EGF and teratocarcinoma: Cripto was described for the first time in the scientific literature in 1989, as a gene of the ’EGF family’ expressed in undifferentiated human NTERA2 teratocarcinoma cells [25], and then further described in 1991 for its role in transforming a normal mouse mammary epithelial-cell line in vitro [26].